The future of biologics: Applications for food allergy - 05/02/15
Abstract |
Allergic diseases affect millions worldwide, with growing evidence of an increase in allergy occurrence over the past few decades. Current treatments for allergy include corticosteroids to reduce inflammation and allergen immunotherapy; however, some subjects experience treatment-resistant inflammation or adverse reactions to these treatments, and there are currently no approved therapeutics for the treatment of food allergy. There is a dire need for new therapeutic approaches for patients with poorly controlled atopic diseases and a need to improve the safety and effectiveness of allergen immunotherapy. Improved understanding of allergy through animal models and clinical trials has unveiled potential targets for new therapies, leading to the development of several biologics to treat allergic diseases. This review focuses on the mechanisms that contribute to allergy, with an emphasis on future targets for biologics for the treatment of food allergy. These biologics include immunotherapy with novel anti-IgE antibodies and analogs, small-molecule inhibitors of cell signaling, anti–type 2 cytokine mAbs, and TH1-promoting adjuvants.
Le texte complet de cet article est disponible en PDF.Key words : Food allergy, immunotherapy, anti-IgE, oral tolerance, allergen sensitization, anaphylaxis, biologics
Abbreviations used : AIT, DARPin, DC, EC, EoE, Foxp3, IEC, ILC, NKT, PAF, TLR, Treg, TSLP
Plan
Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, and William T. Shearer, MD, PhD |
|
Disclosure of potential conflict of interest: A. M. Singh has received research support from the National Institute of Allergy and Infectious Diseases (K23). The rest of the authors declare that they have no relevant conflicts of interest. |
|
Terms in boldface and italics are defined in the glossary on page 313. |
Vol 135 - N° 2
P. 312-323 - février 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?